A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

Prospective, single-arm, open-label, multicenter pilot study was carried out.

Participants were 26 adults aged 40-65 years old with abdominal obesity (male: waist circumference >90 cm, female: waist circumference >85 cm).

Who Took Part

The abstract describes 26 adults taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was an open-label, multicenter and pilot study.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

Topics PubMed links to this paper include Human Growth Hormone, Intra-Abdominal Fat, Obesity, Abdominal and Waist Circumference.

What This Means in Plain Language

The paper is an open-label, multicenter and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 26 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2011 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.